## Chapters
0:00 The Madrigal Pharmaceuticals Story
3:48 Earnings Overview
Madrigal Pharmaceuticals just reported Q1 2026 earnings — eps beats, revenue misses.
The mixed results raise questions — here's our full breakdown of what it means for MDGL.
🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha?sub_confirmation=1
📊 Key Financial Highlights:
• Revenue: $311M
• EPS: $-3.25 vs $-3.61 expected (-10.0% beat)
📈 Free stock screening tools — no signup, no paywall:
https://chargedalpha.com
🎧 Also available as a podcast:
https://chargedalpha.podbean.com
#stocks #MDGL #earnings #stocks #investing #stockmarket #earningsseason #wallstreet #MadrigalPharmaceuticals
---
Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com)
⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies.
Watch on YouTube: https://www.youtube.com/watch?v=xNheejtx3So